Third quarter 2026 earnings call, October 29, 2026

Linde used its third quarter call to concede that the Lincare home healthcare business has become a drag large enough to warrant structural change. The company recorded a $425 million restructuring charge, roughly half of it severance, concentrated in lower-growth regions. The balance relates mainly to portfolio and asset actions at Lincare in the U.S. CEO Sanjiv Lamba opened the call by noting that results three months ago "were not up to the expectation of our owners" and that "that message was received loud and clear." Headline numbers were records, with sales of $9.4 billion, operating profit of $2.8 billion and EPS of $4.59, up 9%. But the operating margin excluding cost pass-through was flat, and management guided the fourth quarter conservatively.

Lincare Leaves the Regional Segments and Could Be Sold

Linde has moved Lincare into the Global Other segment and now has it reporting directly to CFO Matt White. Management framed the move as an accounting consequence of a change in executive oversight, tied to the Chief Operating Decision Maker designation, but it carries strategic weight. White pointed to precedent in the GIST business, which was also shifted into Other with different oversight and was later sold. He was careful not to promise an exit: "We've said we will continue to evaluate strategic options, but we can't assure there will be a strategic option to be had. And so we have to improve this business."

The financial cost is now explicit. Lincare is subtracting about 2% from year-to-date EPS growth, and White said eliminating that headwind "will support the return to double-digit EPS growth for the global organization." Asked about the math, he put the drag at a "very strong 1 to a weak 2" percent for the full year. Lamba said sales at the remaining business will lag the market as the portfolio is trimmed, and that healthcare growth excluding Lincare is mid-single digit versus 2% reported. Lincare remains free cash flow positive. White said depreciation and capex roughly offset, so EBIT is a rough proxy for free cash flow, though working capital is seasonal given the reset of healthcare plan deductibles. Removing Lincare takes about $2.3 billion of annualized sales out of the Americas segment.

The severance savings follow Linde's usual pattern. Cash paybacks are 1 to 2 years, with this program toward the longer end. Savings begin in the fourth quarter, with full run rate in the second half of 2027. White said the benefit will be incremental to the normal productivity embedded in Linde's earnings algorithm, which he described as an ongoing cultural expectation, versus the "episodic" top-down nature of restructuring.

Guidance Embeds Little Credit for the Actions

Fourth quarter EPS guidance of $4.40 to $4.50 implies 5% to 7% growth, a deceleration from the 9% just delivered. The full-year range of $17.82 to $17.92 simply rolls the quarter into year-to-date results. White bridged the sequential decline of about 3% at the midpoint as follows: 1% from a stronger dollar, 1% from a third-quarter equity income spike tied to a customer contract true-up that will not recur, and a final 1% reflecting seasonality and a guarded stance. "We're not yet embedding any meaningful change to Q4 profit," he said, adding that the goal is to beat the range. No economic improvement is assumed, including at Lincare. 2027 guidance will come in February.

Pricing Is Doing More of the Work, With Americas Flattered by Recovery and Optics

Price rose 3% in the quarter, and the Americas reached about 6%. White attributed roughly 2 points to recovery of prior and current cost inflation in power and distribution, mainly in merchant and packaged gases, leaving an underlying run rate near 4%. The recovery is dilutive to Americas margins, which printed at 35%, though net positive to operating profit. The removal of Lincare from the segment's denominator also makes recovery look larger. Management does not expect these costs to persist into the fourth quarter but is prepared for further measures. White noted that merchant and packaged recovery typically lags 3 to 6 months, while on-site is passed through in the month....